Lymphoma

Umbralisib is currently under investigation by the FDA regarding a potentially increased risk of death in patients with lymphomas following data from an ongoing trial investigating its use in chronic lymphocytic leukemia.

Michael R. Bishop, MD, discussed details from the ZUMA-7 and TRANSFORM trials that were presented at the 63rd ASH Annual Meeting.

Michael R. Bishop, MD, highlighted the population of patients with relapsed/refractory B-cell non-Hodgkin lymphoma who were enrolled on the phase 3 BELINDA study and treated with tisagenlecleucel.

An upcoming program from Atlantic Health System physicians apprising key data from the American Society of Hematology Annual Meeting & Exposition brings in faculty from top programs to share research updates.

Sugemalimab showed promise in the phase 2 GEMSTONE-201 trial in a group of patients with extranodal natural killer/T-cell lymphoma; developer CStone is set to submit a new drug application for the treatment to the National Medical Products Administration of China.

Gilead Sciences has announced the voluntary withdrawal of idelisib from the United States market in several indications including follicular lymphoma and small lymphocytic leukemia.

Steven Devine, MD, spoke about which abstracts he found most interesting at ASH 2021.

Sattva S. Neelapu, MD, spoke about continuing to look at results from the ZUMA-5 trial to determine if axicabtagene ciloleucel can cure patients with relapsed or refractory indolent non-Hodgkin lymphoma

Second-line treatment of lisocabtagene maraleucel demonstrated improved quality of life in patients with large B-cell lymphoma.

Patients with previously untreated diffuse large B-cell lymphoma experienced promising responses after being treated with tafasitamab-cxix and lenalidomide plus rituximab, cyclophosphamide, doxorubicin, vincristin, and prednisone.

Patients with high-risk large B-cell lymphoma saw durable responses when treated with axicabtagene ciloleucel.

Sattva S. Neelapu, MD, spoke about which abstracts he was most excited to see presented at the upcoming American Society of Hematology Annual Meeting.

A positive overall response rate was achieved when patients with relapsed/refractory peripheral T-cell lymphoma were treated with duvelisib plus romidespin.

Patients with large B-cell lymphoma who were previously excluded from investigations experienced increased efficacy with the use of axicabtagene ciloleucel.

Treatment with lisocabtagene maraleucel resulted in long-lasting responses in patients with relapsed/refractory large B-cell lymphomas.

Treatment with naratuximab emtansine and rituximab appeared to be well-tolerated with efficacious responses in a population of patients with B-cell non-Hodgkin lymphomas who were ineligible for stem cell transplant or CAR-T cell therapy.

The ZUMA-7 trial demonstrated an event-free survival improvement in patients with relapsed or refractory large B-cell lymphoma treated with axicabtagene ciloleucel.

Patients with relapsed or refractory follicular lymphoma or marginal zone lymphoma had high rates of response and overall survival with axicabtagene ciloleucel at an updated analysis of the ZUMA-5 trial.

A quality-of-life analysis from the phase 3 ZUMA-7 trial of axicabtagene ciloleucel in patients with relapsed or refractory large B-cell lymphoma shows favorability of the CAR T-cell therapy over standard options.

Treatment with the CAR T-cell therapy tisagenlecleucel for relapsed or refractory diffuse large B-cell lymphoma or high-grade B-cell lymphoma was favorable in both the pivotal clinical trial and the real-world setting, according to new data made available during 2021 ASH.

Sattva S. Neelapu, MD, spoke about the ZUMA-5 trial and the long-term follow-up results seen with axicabtagene ciloleucel in patients with relapsed or refractory indolent non-Hodgkin lymphoma.

Patients with autologous stem cell transplant–ineligible relapsed/refractory diffuse large B-cell lymphoma appear to benefit from treatment with tafasitamab and lenalidomide.

Second-line treatment with liscocabtagene maraleucel improved survival compared with the standard of care for patients with relapsed or refractory large B-cell lymphoma.

A United States indication for duvelisib in previously treated relapsed/refractory follicular lymphoma has been voluntarily withdrawn by developer Secura Bio following an assessment of the drug and subsequent consultation with the FDA.

The FDA has approved rituximab plus chemotherapy for previously untreated pediatric CD20-postive diffuse large B-cell lymphoma, Burkitt lymphoma, Burkitt-like lymphoma, and mature B-cell acute leukemia following results from the phase 3 Inter-B-NHL Ritux 2010 study.

The FDA granted priority review to a new drug application for parsaclisib in patients with mantle cell lymphoma and other non-Hodgkin lymphomas.

Patients with relapsed or refractory follicular lymphoma who have received 2 prior lines of therapy appear to benefit from treatment with tisagenlecleucel, which was granted a priority review by the FDA.

As treatment for T-cell non-Hodgkin lymphomas continues to expand, disparities and inequities continue to grow for those within certain racial groups and of a certain socioeconomic status.

Findings from the phase 1 CARBON trial indicated that patients with relapsed/refractory CD19-positive B-cell malignancies may benefit from CTX110 CAR T-cell therapy.

Caron A. Jacobson, MD, MMSC, highlights data supporting the use of CAR T-cell therapy in patients with indolent lymphoma.